Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 3874 results
FDA approves abuse deterrent labeling for Pfizer's Embeda
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved an updated label for Pfizer's Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies.
Drug Research > Drug Discovery & Development > News
NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement
NeuroSigma a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, Pharmacyclics and Janssen collaborate for new non-hodgkin lymphoma drug
By PBR Staff Writer
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have entered into collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).
Drug Research > Drug Discovery & Development > News
HemoShear completes initial development phase of new cancer drug discovery platform
By PBR Staff Writer
HemoShear has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.
Drug Research > Drug Discovery & Development > News
Pharmaceutical firms to use UC San Diego-led resource to share data for drug design
By PBR Staff Writer
Pharmaceutical companies will collaborate with researchers at the University of California, San Diego to provide previously unreleased proprietary data for drug discovery through a new $3.7m effort funded by the National Institutes for Health.
Drug Research > Drug Discovery & Development > News
Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma.
Drug Research > Drug Discovery & Development > News
EMD Serono, ICR, Wellcome Trust collaborate to develop anti-cancer drugs
By PBR Staff Writer
Merck subsidiary EMD Serono, the Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and license agreement for developing new drug candidates to treat different forms of cancer.
Drug Research > Drug Discovery & Development > News
DiscoveryBioMed awarded Dual SBIR awards for PKD drug discovery and validation
DiscoveryBioMed learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD).
Drug Research > Drug Discovery & Development > News
BrainStorm reports last patient visit in Phase IIa ALS trial
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadassah Medical Center in Jerusalem.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics report top-line results from Phase II trial of EBI-005
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced top-line results from a Phase 2 study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis.
Drug Research > Drug Discovery & Development > News
China Oncology to develop and commercialize Sorrento's anti-PD-L1 antibody
By PBR Staff Writer
Lee's Pharma affiliate China Oncology Focus has secured license from US-based Sorrento Therapeutics for its fully human immune-oncology anti-PD-L1 monoclonal antibody (mAb) STI-A1014.
Drug Research > Drug Discovery & Development > News
Neurocrine begins tourette syndrome clinical trial of NBI-98854
Neurocrine Biosciences has initiated a clinical trial of NBI-98854, a proprietary small molecule Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, in both children and adolescents with Tourette syndrome.
Drug Research > Drug Discovery & Development > News
Regeneron, Sanofi report positive Phase II trial results of dupilumab in CSwNP patients
By PBR Staff Writer
US-based Regeneron Pharmaceuticals and French pharmaceutical firm Sanofi have reported positive results from a Phase IIa proof-of-concept trial of dupilumab in patients with chronic sinusitis with nasal polyps (CSwNP).
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb reports positive phase III data for Opdivo in advanced melanoma patients
Bristol-Myers Squibb Company has announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab).
Drug Research > Drug Discovery & Development > News
Kamada announces second extension of strategic agreement with Baxter
Kamada, a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia to Baxter in its strategic agreement with the biopharmaceutical business of Baxter International.
Drug Research > Drug Discovery & Development > News
91-105 of 3874 results